Plasma Therapy Market to Reach USD 1,332.81 Million by 2033, Growing at 13.21% CAGR - Straits Research

According to the latest report by Straits Research, the global plasma therapy market was valued at USD 436.32 million in 2024 and is projected to grow from USD 493.96 million in 2025 to USD 1,332.81 million by 2033, exhibiting a robust CAGR of 13.21% during the forecast period (2025-2033). The market expansion is primarily driven by the rising prevalence of immunodeficiency disorders, technological advancements, and increased adoption of plasma-derived therapies for treating chronic and life-threatening diseases.

Plasma therapy utilizes blood-derived antibodies to treat a wide range of severe medical conditions. It has gained significant attention as a promising solution for improving life expectancy and recovery outcomes in patients suffering from various disorders. The rising cases of accidental blood loss and the growing global healthcare expenditure further contribute to the increasing demand for effective plasma-derived treatments. Plasma therapies are being widely implemented across orthopedics, dermatology, and chronic infectious disease management, strengthening their role in modern medical practice.

Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart) : https://straitsresearch.com/report/plasma-therapy-market/request-sample

Market Dynamics

Driving Factors

One of the major growth drivers for the plasma therapy market is the rising prevalence of immunodeficiency disorders. The demand for plasma-derived immunoglobulins has increased significantly as cases of primary immunodeficiency continue to grow worldwide. These disorders marked by recurrent infections, autoimmune responses, and inflammation can be effectively managed through immunoglobulin replacement therapy. As a result, the need for specialized immunoglobulin products has surged, promoting market growth.

In addition, technological innovations by leading industry players have accelerated plasma processing and fractionation. Major companies are focusing on advanced systems that enhance plasma extraction efficiency. For example, GEA introduced a new separator technology for Biopharma S.A. in 2021, enabling faster and safer plasma processing. Similarly, automated systems such as the Rika Plasma Donation System are being adopted globally to meet the growing demand for plasma-derived therapies.

Challenges

The market faces certain restraints, primarily due to the rising use of recombinant therapies as substitutes for plasma-derived medicines. Recombinant products offer several advantages, including reduced immunogenicity, lower risk of disease transmission, and longer half-lives, making them a safer and more convenient alternative. This shift toward recombinant treatments could limit the growth potential of plasma-derived products in the coming years.

Opportunities

Nevertheless, the growing demand for plasma-derived pharmaceuticals (PDMPs) such as albumin, immunoglobulins, and coagulation factors presents lucrative opportunities. The World Health Organization (WHO) recognizes these plasma-derived products as essential medicines for healthcare systems globally. The expanding use of immunoglobulins in immunodeficiency therapy and the rising applications in prenatal and intensive care continue to fuel the plasma therapy market's growth prospects.

For more insights and detailed analysis on the Market, visit : https://straitsresearch.com/report/plasma-therapy-market

Regional Insights

North America dominates the global plasma therapy market and is expected to grow at a CAGR of 13.6% through 2033. The region's leadership is attributed to the presence of major market players, a well-established healthcare infrastructure, and increasing immunoglobulin consumption. The U.S. and Canada are driving growth through expanding plasma collection networks, rising awareness, and supportive regulatory frameworks.

The Asia-Pacific region is projected to experience the fastest growth, with a CAGR of 14.42% during the forecast period. Rising medical tourism, expanding cosmetic procedures, and strong government initiatives are driving market expansion in countries like China, India, Japan, South Korea, and Thailand. Japan, in particular, has made significant strides through the establishment of the Japan Blood Products Organization, which ensures a safe and sufficient supply of plasma-derived pharmaceuticals.

Segmental Highlights

By Type: Pure platelet-rich plasma leads the market, expected to grow at a CAGR of 13.8%, driven by its wide application in cosmetic, cardiovascular, and wound healing procedures.

By Source: Autologous plasma dominates with a CAGR of 14.53%, owing to lower disease transmission risks and higher safety levels compared to allogenic sources.

By Application: Orthopedic treatments hold the largest market share, growing at a CAGR of 14.05%, while dermatology applications are expected to witness rapid expansion due to the increasing adoption of plasma therapy in facial rejuvenation.

By End User: Hospitals and clinics account for the largest share, with a CAGR of 14.39%, due to rising off-label use of plasma products and improvements in clinical infrastructure.

Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart) : https://straitsresearch.com/report/plasma-therapy-market/request-sample

Key Players

BioLife Plasma Services
Grifols International S.A.
Biotest
CSL Ltd.
Cambryn Biologics LLC
Bio Products Laboratory Ltd.
China Biologic Products Inc.
Kedrion S.p.A.
Octapharma
LFB biopharmaceutical

Browse More Insights & Reports :

Cold Plasma Market : https://straitsresearch.com/report/cold-plasma-market

Colloids (Blood Plasma) Market : https://straitsresearch.com/report/colloids-blood-plasma-market

About Us

For over a decade, Straits Research has been a trusted partner to more than 2,000 small and large enterprises, empowering senior leaders and decision-makers with actionable intelligence to navigate complex markets. Our structured syndicate reports, published year-round, cover critical sectors such as chemicals, materials, food and beverage, healthcare, pharmaceuticals, automotive, technology, aerospace, and defense. Combined with our custom research tailored to client-specific needs, we deliver insights that drive business progress and informed decision-making.

Contact Us

Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.

+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

This release was published on openPR.